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To report the clinical, radiologic, biochemical, and molecular characteristics in a 46-year-old
participant with adult-onset Leigh syndrome (LS), followed by parkinsonism.
Methods
Case description with diagnostic workup included blood and CSF analysis, skeletal muscle
investigations, blue native polyacrylamide gel electrophoresis, whole exome sequencing tar-
geting nuclear genes involved in mitochondrial transcription and translation, cerebral MRI,
123I-FP-CIT brain single-photon emission computed tomography (SPECT), and C-11
raclopride positron emission tomography (PET).
Results
The participant was found to have a defect in the oxidative phosphorylation caused by
a c.626C>T mutation in the gene coding for mitochondrial methionyl-tRNA formyltransferase
(MTFMT), which is a pathogenic mutation aﬀecting intramitochondrial protein translation.
The proband had a normal concentration of lactate in blood and no abnormal microscopic
ﬁndings in skeletal muscle. Cerebral MRI showed bilateral lesions in the striatum, mesen-
cephalon, pons, and medial thalamus. Lactate concentration in CSF was increased. FP-CIT
SPECT and C-11 raclopride PET demonstrated a defect in the dopaminergic system.
Conclusions
We report on a case with adult-onset LS related to a MTFMT mutation. Two years after the
onset of symptoms of LS, the proband developed a parkinson-like disease. The c.626C>T
mutation is the most common pathogenic mutation found in 22 patients reported earlier in the
literature with a defect inMTFMT. The age of the previously reported cases varied between 14
months and 24 years. Our report expands the phenotypical spectrum of MTFMT-related
neurologic disease and provides clinical evidence for involvement ofMTFMT in extrapyramidal
syndromes.
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Leigh syndrome (LS) is a devastating neurometabolic disorder
occurring mainly in infants and young children. Aﬀected children
initially develop normally but present between the age of 2 and 9
months with signs of motor regression, weakness, hypotonia, weak
cry, and failure to thrive. Shortly thereafter, signs of brainstem
dysfunction are seen, including respiratory pattern abnormalities,
nystagmus, ptosis, and ophthalmoparesis. Other neurologic man-
ifestations include pyramidal tract signs, ataxia, dystonia, tremor,
and seizures, eventually progressing to death, usually within 2 years
after onset of symptoms. Pathologic hallmarks of the disease are
bilaterally symmetrical foci characterized by spongiform necrosis
with capillary proliferation in the midbrain and striatum.1,2
The incidence is 1 in 40,000.3 Rarely, the onset of symptoms
is in late childhood, adolescence, or adulthood.
Gene defects associated with LS are located in mitochondrial
or nuclear genes involved in the biosynthesis of oxidative
phosphorylation (OXPHOS) complexes I, II, III, IV, and V, or
involved in the biosynthesis of coenzyme Q or pyruvate de-
hydrogenase complex. Mutations in the gene coding for mi-
tochondrial methionyl-tRNA formyltransferase (MTFMT)
were reported earlier as the cause of LS.4–6
In this study, we describe a patient with adult-onset LS caused by
a homozygous pathogenic mutation in MTFMT. Our observa-
tion broadens the clinical spectrum of MTFMT-related disease.
Methods
Case description with a diagnostic workup included results
from blood and CSF analysis, skeletal muscle investigations,
blue native polyacrylamide gel electrophoresis (BN-PAGE),
whole exome sequencing (WES) targeting nuclear genes in-
volved in mitochondrial transcription and translation, brainMRI
(bMRI), 123I-FP-CIT brain single-photon emission computed
tomography (SPECT), and C-11 raclopride positron emission
tomography (PET). Written informed consent for research was
obtained from the participant and her guardian.
Data availability




A 44-year-old woman was admitted to the department of
neurology after 1 week of dizziness, vomiting, somnolence,
and subfebrility (37.8°C). Before admission, she had complained
of double vision. Divergent eye motility was observed intermit-
tently. Her medical history revealed mild cognitive impairment,
early-onset bilateral sensorineural hearing loss, autism spectrum
disorder, obsessive-compulsive behavior, depression, osteoporo-
sis, obesity, and mild chronic obstructive pulmonary disease.
Vitamin B12 hypovitaminosis was diagnosed in the past as the
cause of pernicious anemia. Neurologic examination on admis-
sion to the hospital was limited because of poor cooperation and
somnolence. Slight nuchal rigidity, gait ataxia, hyperreﬂexia,
plantar reﬂexes in extension, and absence of sensorimotor dys-
function were noticed. Neuroophthalmologic examination
showed upward gaze palsy, downward gaze paresis, bilateral mi-
osis not reacting to light and preserved convergence, and ability to
abduct the eyes. Coordination could not be tested because of
insuﬃcient cooperation. Urinary retention was detected on ar-
rival. In the 3 weeks after admission, a deterioration of gait and
balance was seen, as well as lack of initiative. Slight speech diﬃ-
culties (hypophonia and tachylalia) were detected, as well as slow
movements. Diﬀerential diagnosis included Wernicke encepha-
lopathy, acute demyelinating disease, and LS. Acute stroke was
excluded with acute brain CT. IV vitamin B-complex, including
thiamin, was started but did not change symptomswithin the ﬁrst
days. Later on, her clinical condition stabilized. Gait, balance, and
speech recovered slowly over a period of 1 month, although
a high-pitched tachylalia remained present and appeared to be
already known before admission. Gradual improvement of dip-
lopia and bladder dysfunction was seen, although the sensori-
neural hearing loss was worsening.
Technical investigations
bMRI showed nonacute lacunar or cystic T2-hyperintense
lesions in the basal ganglia (caudate nucleus and putamen)
and remarkable acute symmetrical ﬂuid attenuated inversion
recovery (FLAIR)-/T2-hyperintense lesions in the mesen-
cephalon, suggestive of Leigh disease (ﬁgure, A and B).
Follow-up bMRI 1 month later showed that brainstem lesions
were more pronounced in the mesencephalon and pons,
extending into the medial thalamus bilaterally. bMRI 3
months after symptom onset showed tissue loss and gliosis,
with reduced FLAIR hyperintense signals in the mesence-
phalic area, in both thalami and new lesions in the middle
cerebellar peduncles (ﬁgure, C and D). CSF analysis on the
ﬁrst admission was normal, except for increased lactate con-
centration (38 mg/dL, normal 10–22), conﬁrmed a few days
later (33 mg/dL). Serum lactate, vitamin B12, and thiamin
were normal. Ophthalmologic examination showed abnormal
eye motility but no signs of optic atrophy or of retinitis pig-
mentosa. Ultrasound examination of the heart revealed mild
Glossary
bMRI = brain magnetic resonance imaging; BN-PAGE = blue native polyacrylamide gel electrophoresis; EPS = extrapyramidal
symptom; FLAIR = ﬂuid attenuated inversion recovery; FP-CIT = N-(3-ﬂuoropropyl)-2beta-carbomethoxy-3beta-(4-
iodophenyl)nortropane; LS = Leigh syndrome; OXPHOS = oxidative phosphorylation; PD = Parkinson disease; PET =
positron emission tomography; SPECT = single-photon emission computed tomography; WES = whole exome sequencing.
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left ventricular hypertrophy (interventricular septum and left
ventricular posterior wall thickness of 13 mm). The urinary
bladder was atonic. The clinical presentation and technical and
biochemical investigations were suggestive of a mitochondrial
disease compatible with LS. A skeletal muscle biopsy (M. quad-
riceps femoris) and skin biopsy were performed. Histologic
analysis of skeletal muscle showed no abnormalities. Ragged red
ﬁbers were not detected. Spectrophotometric measurement of
the OXPHOS complex activities revealed a combined deﬁciency
of complexes I and IV. In cultured skin ﬁbroblasts, a signiﬁcantly
decreased activity of complex IV was found (complex I not
assessed) (table). BN-PAGE, followed by in-gel activity staining
using isolated mitochondria from cultured skin ﬁbroblasts, con-
ﬁrmed decreased activity of complexes I and IV, and in addition,
showed the presence of complex V subcomplexes. These ﬁnd-
ings together are the hallmark of defective intramitochondrial
protein synthesis. Sequencing of the complete mitochondrial
genome with massive parallel sequencing methodology in leu-
kocytes and skeletal muscle did not reveal a pathogenic alter-
ation. DNA sequencing of the POLG gene was normal, and
comparative genomic hybridization microarray analysis showed
no abnormalities. Molecular workup by WES targeting nuclear
genes revealed a homozygous missense mutation (c.626C>T,
p.Ser209Leu) in MTFMT (NM 139242.3). Biotin-thiamin re-
sponsive basal ganglia disease caused by a mutation in SLC19A3
was excluded. Parents were not available for testing.
Long-term follow-up
Two years after the onset of symptoms of LS, at the age of 46
years, extrapyramidal symptoms (EPS) were seen characterized
by marked hypomimia, mild bradykinesia, diﬃculties with ﬁne
motor skills, discrete cogwheel rigidity, diminished arm swing
amplitude, disturbed ﬁnger movements, slight dysdiadochoki-
nesis, and hypophonia. Tremor was not observed. Gait and
balance were near normal. The eﬀect of EPS on daily activities
was limited, and, therefore, medical treatment was not started.
EPS remained stable over the course of 5 years after the onset.
Thereafter, a mild positional tremor of both hands (left > right)
was noticed and bradykinesia worsened. Brain I-123 FP-CIT
SPECT scan showed bilateral symmetrical reduced FP-CIT
binding in the basal ganglia (ﬁgure, E). Brain C-11 raclopride
PET revealed severe bilateral neostriatal reduction of C-11
raclopride (ﬁgure, F). A therapeutic trial with levodopa was
started with limited beneﬁcial eﬀect on tremor and bradykinesia.
Discussion
LS is usually reported as infantile subacute necrotizing ence-
phalomyelopathy, a neurodegenerative disorder clinically char-
acterized by variable neurologic signs. Bilateral lesions in the
striatum are typically seen on brain imaging studies. The onset
of symptoms in infancy or early childhood is usually triggered by
metabolic or infectious stress, followed by rapid neurologic
deterioration, often leading to death.7 Long-term survival after
early-onset LS and atypical late-onset variants has been repor-
ted.8 The number of patients with late-childhood–, adolescent-,
or adult-onset LS is limited, and only in a few, the genetic defect
was identiﬁed. The MTFMT gene product is essential for eﬃ-
cient mitochondrial translation initiation and function. The
protein is involved in formylation of a portion of the Met-
tRNAMet pool to generate formylmethionyl-tRNA needed for
initiation of protein synthesis in mitochondria.4,9 We report here
the oldest patient so far with a homozygous pathogenicmutation
in MTFMT who developed adult-onset LS.
Pathogenic mutations in theMTFMT gene were ﬁrst reported
in 2 children, aged 5 and 9 years, with LS and combined
Figure Structural and nuclear brain imaging
Brain MRI on admission showing T2 nonacute neostriatal cystic lesions (A),
hyperintense lesions in mesencephalon and pons (B and C), and subacute
lesions in middle cerebellar peduncles (D). I-123 FP-CIT SPECT (E) and C-11
raclopride PET (F) showing bilateral reduced presynaptic dopamine trans-
port and bilateral postsynaptic dopaminergic impairment. SPECT = single-
photon emission computed tomography.
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OXPHOS deﬁciency.4 To date, 22 patients with MTFMT
mutations were reported in the literature. The age at onset varied
between birth and 17 years. Most of them presented with ataxia,
muscular hypotonia, and cognitive impairment, but recently
reported cases support an expanding phenotypical spectrum,
including MRI features mimicking demyelinating disease, car-
diomyopathy, and even an association with renal dysplasia and
moyamoya disease in a 4-year-old child.6,9–12 Recently, a girl was
reported with mild neurologic phenotype at age 7 years and
involvement of the visual pathways starting at the age of 18
years.13 MTFMT-patients with adolescent-onset symptoms are
rare. They have developmental delay already present in child-
hood, slight intellectual disability, and behavioral problems.6,14
In the proband, molecular workup by WES and in silico
analysis of the genes involved in mitochondrial transcription
and translation revealed a homozygous missense mutation
(c.626C>T, p.(Ser209Leu)) in the gene encoding MTFMT.
This mutation is predicted to eliminate 2 overlapping exonic
splicing enhancers (GTCAA and TCAAGA) and to generate
an exonic splicing suppressor (GTTGTT) causing loss of
function through altered splicing, leading to skipping of exon
4 and introduction of a premature stop codon resulting in
truncation of the protein (p.Arg181Serfs*5) as reported
earlier.4,15 The c.626C>T variant is present in the heterozy-
gous state in 0.1% of the European population, making it
a strong candidate gene for patients presenting with LS in
combination with combined OXPHOS deﬁciencies involving
complexes I and IV.6
The clinical course of LS in the proband initially seemed to be
self-limiting and benign. Of interest, the proband developed
an extrapyramidal syndrome within 2 years after onset of LS
characterized by symmetrical parkinsonism signs with limited
levodopa responsiveness, distinguishing it from classical
Parkinson disease (PD). Parkinsonian symptoms in MTFMT-
deﬁcient patients have not been reported so far. In most of the
cases with adult-onset LS, EPS were limited to dystonia.16 In
only 1 report, extrapyramidal rigidity was described in an adult
with LS. However, the molecular defect was not speciﬁed.17 In
the reported participant, EPS developed after stabilization of
the symptoms attributed to LS, as was the case in the proband
reported here. Juvenile parkinsonism with beneﬁcial eﬀect of
treatment with levodopa was reported in an adolescent with
Leigh-like phenotype caused by a point mutation in the mi-
tochondrial tRNAIle (m.4296G>A).18
To evaluate the dopaminergic system in the proband, FP-CIT
SPECT and C-11 raclopride PET were performed. Sym-
metrical decreased density of presynaptic dopamine trans-
porter terminals with bilaterally reduced FP-CIT binding was
found. C-11 raclopride PET labeling of dopamine D2
receptors showed severe bilateral neostriatal reduction of
C-11 raclopride, revealing postsynaptic dopaminergic im-
pairment. This result is similar to that seen in the atypical
parkinsonian syndromes, such as multiple system atrophy or
progressive supranuclear palsy.19
Limited evidence on dopamine transport imaging in LS is
available. A study on 123I-FP-CIT striatal binding in 14
patients (age 35–69 years, median 48 years) with mitochon-
drial disorders and complex I deﬁciency failed to demonstrate
dopaminergic cell loss. However, none of these patients suf-
fered from LS or showed clear signs of parkinsonism.20 In the
participant reported here, cystic lesions in the neostriatum
reﬂecting basal ganglia degeneration caused by mitochondrial
dysfunction are likely to be involved in EPS. Of interest,
a recent study on the etiologic role of epigenetic inﬂuences in
PD showed a role of several microRNAs involved in a network
of genes associated with PD. It was shown that the expression
Table Spectrophotometric analysis of the activities of the OXPHOS complexes in skeletal muscle and cultured skin
fibroblasts in the proband and in the healthy controls
Complex I II II + III III IV V CS
Skeletal muscle homogenate
Proband 4 27 18 46 40 ND 94
Controls
Mean 29 34 33 96 167 ND 174
P5-P95 15–52 18–58 18–50 50–145 82–266 ND 92–273
Cultured skin fibroblasts
Proband ND 27 32 42 44 ND 82
Controls
Mean ND 15 17 47 69 ND 82
P5-P95 ND 12–21 11–30 28–67 48–96 ND 59–109
Abbreviations: CS = citrate synthase; ND = not determined; OXPHOS = oxidative phosphorylation.
All values expressed as nmol/min/mg protein.
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of MTFMT (inﬂuenced by miR-488) was downregulated in
the cingulate gyrus of patients with PD as compared to
healthy controls. Dysregulation of 1 or more of the genes in
the PD-genetic network, including MTFMT, might interfere
with extrapyramidal neuronal integrity and function.21 The
ﬁndings in the participant described here provide additional
clinical evidence for the hypothesis that MTFMT is involved
in PD-related genetic network and that MTFMT dysregula-
tion might be an etiologic factor in parkinsonism.
We cannot rule out that the older age of the proband as
compared to other reported patients may have played a role in
the development of atypical parkinsonism. At present, it is
unclear whether parkinsonism is part of the MTFMT phe-
notype. Natural history data on patients with MTFMT
mutations and advanced age are lacking. Our data suggest that
dopaminergic neurons in patients with LS caused by patho-
genic MTFMT mutations may be more susceptible to PD
because of the impaired OXPHOS system, ultimately leading
to a clinically signiﬁcant extrapyramidal syndrome.
Adult-onset LS can be seen in patients with c.626C>T
mutation in MTFMT. We showed that the aﬀected patient
had a defect in the dopaminergic system associated with
atypical parkinsonism. Further research on the natural history
of patients with pathogenic MTFMT mutations is needed to
clarify the full clinical spectrum and underlying physiopath-
ologic mechanisms.
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